Moderna Inc (MRNA)

Return on equity (ROE)

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	US$ in thousands	-3,561,000	-4,714,000	8,362,000	12,202,000	-747,064
Total stockholders’ equity	US$ in thousands	10,901,000	13,854,000	19,123,000	14,145,000	2,561,000
ROE		-32.67%	-34.03%	43.73%	86.26%	-29.17%

December 31, 2024 calculation

ROE = Net income ÷ Total stockholders’ equity
= $-3,561,000K ÷ $10,901,000K
= -32.67%

Moderna Inc's return on equity (ROE) has fluctuated significantly over the past five years. In 2020, the ROE was -29.17%, indicating that the company experienced a negative return relative to its equity during that period. However, in 2021, the ROE improved drastically to 86.26%, reflecting a strong profitability and efficiency in generating returns on shareholders' equity.

In 2022, the ROE remained relatively high at 43.73%, showing that Moderna continued to generate positive returns on its equity investment. However, there was a decline in 2023 where the ROE dropped to -34.03%, signifying a reversal in profitability and efficiency compared to the previous year.

Furthermore, in 2024, the ROE slightly decreased to -32.67%, indicating another year of negative return on equity for the company. Overall, the ROE trend for Moderna Inc reflects variability in financial performance and efficiency in utilizing shareholders' equity effectively to generate profits. Further analysis and investigation into the factors influencing these fluctuations would be necessary to fully understand the company's financial health and prospects.